Summary
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and
regimen of XmAb23104, to describe safety and tolerability, to assess PK and
immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy
and combination therapy with ipilimumab in subjects with selected advanced solid tumors.